



Meet your stakeholder
needs with confidence

Let's talk at ISPOR Montreal

Join IQVIA at ISPOR 2025

Real world evidence. Real confidence. Real results.

Join IQVIA's RWE experts to discover new insights from **our live presentations** and **46 posters** featuring our latest research.



WORKSHOP SESSION

THURSDAY, MAY 15 • 1:45PM–2:45PM

Best Research Practice

Does the practice of implementation sciences have a place in industry-sponsored research?

Moderator: Ana Maria Rodriguez-Leboeuf, IQVIA, Spain
Speakers: Mahrukh Zahid, Novartis, Switzerland;
Bridget Gaglio, Evidera, USA



PODIUM SESSION

THURSDAY, MAY 15 • 10:15AM–11:15AM

Real-World Evidence to Inform Decisions: Focus on Oncology

P30: Navigating Real-World Data (RWD) Complexities: Operational Assessment Strategy to Identify Fit-For-Purpose Data Sources for Real-World Evidence (RWE) Studies With Regulatory Purpose (OASIS)

Presenter: Summer Drummond, IQVIA, USA

Ask for a demo of our best-in-class technologies



IQVIA Market Access Insights

A clearer path to market access

Improve market access success with comprehensive insights into HTA decision-making



IQVIA AI-Assisted Scientific Literature Review

Accelerate and enhance the scientific literature review process

Gain faster insight from massive volumes of published scientific literature — 70% faster extraction per document



IQVIA Health Research Space

Direct-to-participant research platform

Deliver effective, high-quality direct-to-participant and decentralized study designs in a real world setting

46 IQVIA Poster Presentations

Generating the right evidence for your stakeholder needs



POSTER SESSION 1 • WEDNESDAY, MAY 14 • 10:30AM–1:30PM

PRESENTING AUTHORS WILL ATTEND THEIR POSTERS FROM 12:30PM–1:30PM

TOPIC	CODE	TITLE	AUTHORS
CLINICAL OUTCOMES	CO41	REAL-WORLD CLINICAL AND DEMOGRAPHIC CHARACTERISTICS ASSOCIATED WITH PROGRESSION TO TYPE 2 DIABETES IN PATIENTS WITH PREDIABETES DISEASE: NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS, DIABETES/ENDOCRINE/METABOLIC DISORDERS (INCLUDING OBESITY)	Dunn T, Chen J, Divino V, Doshi R, Noone J, Radin M, Tian D, Xie L, Solis-Herrera C
ECONOMIC EVALUATION	EE28	INCIDENCE, PREVALENCE, AND ECONOMIC BURDEN OF GRANULOMATOSIS WITH POLYANGIITIS AND MICROSCOPIC POLYANGIITIS IN THE UNITED STATES DISEASE: RARE & ORPHAN DISEASES, URINARY/KIDNEY DISORDERS & CONDITIONS/SPECIALIZED TREATMENT AREAS	Ibiloye E, Kathe N, Multani J, Chen C, Yasuda M, Chang H, Bozeman A, Oh S, Wallace Z
EPIDEMIOLOGY & PUBLIC HEALTH	EPH3	ASSESSING PRESCRIBING TRENDS FOR SELECT GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS (GLP-1S) BY PATIENT DEMOGRAPHICS, PROVIDERS, AND INDICATION DISEASE: PUBLIC HEALTH, SAFETY & PHARMACOEPIDEMOLOGY	Kumar A, Grant K, Jackson C, LaFazia A
	EPH34	SYSTEMATIC LITERATURE REVIEW ON THE ECONOMIC BURDEN OF MYOPIA DISEASE: PEDIATRICS, SENSORY SYSTEM DISORDERS (EAR, EYE, DENTAL, SKIN)	de Milliano T, Wielink K, Li J, Ernst F, Veeranki P, Mulkalappalli N, Pagidigumula R, Lymperopoulou C, Puneekar Y
HEALTH POLICY & REGULATORY	HPR17	ASSESSMENT OF CONDITIONAL LISTING FOR HIGHLY UNCERTAIN AND HIGH-PRICED DRUGS IN TAIWAN DISEASE: NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS	Chen K, Hsu J, Chou K
	HPR30	ADVANCING REAL WORLD EVIDENCE: COMPARATIVE INSIGHTS INTO GLOBAL PRACTICES AND CHINA'S STRATEGIC PROGRESS DISEASE: NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS	Zhu J, Yuan W, Wang Y, Shi X, Yang S, Yin Z, Cai S, Yun H, Liang H
HEALTH SERVICE DELIVERY & PROCESS OF CARE	HSD18	VARIATION IN RECOMBINANT ZOSTER VACCINE UPTAKE AND COMPLETION BY UTILIZATION OF OFFICE-BASED VACCINATION DISEASE: VACCINES	Stempniewicz K, McGuinness C, Chen C, Yasuda M, Tian D, Verdi D, Gatwood J
	HSD21	A QUALITATIVE ASSESSMENT OF EMERGENCY PHYSICIAN PERCEPTIONS AND EXPERIENCES WITH ACUTE PAIN MANAGEMENT DISEASE: NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS, SYSTEMIC DISORDERS/CONDITIONS 	Keating S, Weiner S, Garcia E, Jacobs KD, Brennan E, Tesler-Waldman L
MEDICAL TECHNOLOGIES	MT5	REAL-TIME TECHNOLOGY ADOPTION: ASSESSING EARLY REAL-WORLD TRENDS IN RENAL DENERVATION THERAPY FOLLOWING INITIAL DEVICE APPROVAL DISEASE: CARDIOVASCULAR DISORDERS (INCLUDING MI, STROKE, CIRCULATORY)	Sweeny M, Castro M, McGonigle J, Hurst F, Edwards M, Mack C
METHODOLOGICAL & STATISTICAL RESEARCH	MSR7	TRANSFORMING REGULATORY INTELLIGENCE WITH AI DRIVEN METHODOLOGIES IN HEOR DISEASE: NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS	Biswal D, Arbuckle L
PATIENT-CENTERED RESEARCH	PCR5	PERSPECTIVES OF ADULT PATIENTS AND CAREGIVERS ON THE MANAGEMENT AND CHALLENGES ASSOCIATED WITH NEUROFIBROMATOSIS TYPE 1 AND PLEXIFORM NEUROFIBROMA: A MULTINATIONAL, QUALITATIVE STUDY DISEASE: NEUROLOGICAL DISORDERS, SDC: ONCOLOGY, SDC: RARE & ORPHAN DISEASES	Adeyemi A, Erdmann M, Burckhardt S, Ferner R, Crites A
	PCR14	DEVELOPMENT OF THE MASTOCYTOSIS SYMPTOM SEVERITY DAILY DIARY (MS2D2) FOR NON-ADVANCED SYSTEMIC MASTOCYTOSIS (NONADVSM) PATIENTS AND ESTABLISHING CONTENT VALIDITY DISEASE: RARE & ORPHAN DISEASES, SDC: SYSTEMIC DISORDERS/CONDITIONS (ANESTHESIA, AUTO-IMMUNE DISORDERS (N.E.C.), HEMATOLOGICAL DISORDERS (NON-ONCOLOGIC), PAIN	Ruzich E, Sparling N, Paty J, Akin C, Nicoloro-SantaBarbara J, Zhang J, Easton R, Lim-Watson M, Carden M, Siebenhaar F
	PCR18	COMPARATIVE ANALYSIS OF SMARTPHONE APPLICATION AND WEB-BASED ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) MODALITIES DISEASE: MULTIPLE/OTHER SPECIALIZED TREATMENTS	Jain-Figueroa I, Kummer S, Kündig A, Knaus C, Chan A, Reaney M, O'Neill D, Sjöström-Bujacz A, Dumi G



This research was selected as a Top 5% finalist for the ISPOR Research Presentation Awards

POSTER SESSION 1 • WEDNESDAY, MAY 14 • 10:30AM–1:30PM *continued*

 PRESENTING AUTHORS WILL ATTEND THEIR POSTERS FROM 12:30PM–1:30PM

TOPIC	CODE	TITLE	AUTHORS
REAL WORLD DATA & INFORMATION SYSTEMS	RWD14	ESTIMATING HEALTHCARE RESOURCE UTILIZATION AND DIRECT COSTS OF CHRONIC MYELOID LEUKEMIA IN THE BRAZILIAN PUBLIC HEALTH SYSTEM DISEASE: ONCOLOGY, RARE & ORPHAN DISEASES	Martins J, Bigoni A, de Oliveira D, Ornelas A, Almeida A, Alves D, Matheus G
	RWD21	DEVELOPMENT AND VALIDATION OF A CLAIMS-BASED APPROACH TO IDENTIFY PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER (MTNBC) DISEASE: NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS, ONCOLOGY	Tse J, Shaikh N, Tian D, Collin S, Near A
	RWD22	DEVELOPMENT AND VALIDATION OF A CLAIMS-BASED APPROACH TO IDENTIFY PATIENTS WITH METASTATIC HR+ HER2- BREAST CANCER DISEASE: NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS, ONCOLOGY	Tse J, Shaikh N, Tian D, Collin S, Near A
	RWD34	ADVANCING THE DEVELOPMENT OF REAL-WORLD DATA FOR CANCER CARE IN CHINA: CHALLENGES AND OPPORTUNITIES DISEASE: ONCOLOGY	Lu W, Gui D, Yang S, Li J, Pang L, Chen C, Tong C, Guo Y, Xie Y, Yin Z

POSTER SESSION 2 • WEDNESDAY, MAY 14 • 4:00PM–7:00PM

 PRESENTING AUTHORS WILL ATTEND THEIR POSTERS FROM 6:00PM–7:00PM

TOPIC	CODE	TITLE	AUTHORS
ECONOMIC EVALUATION	EE151	HEALTHCARE RESOURCE OPTIMIZATION OF DIFFERENT FORMULATIONS: DARATUMUMAB SC COMPARED TO DARATUMUMAB IV FOR TREATING MULTIPLE MYELOMA DISEASE: ONCOLOGY, STA: BIOLOGICS & BIOSIMILARS	Mo X, Wang H, Yang H, Liu J, Ming J
	EE184	COSTS OF CARE FOR PATIENTS WITH TRIPLE NEGATIVE METASTATIC BREAST CANCER: A RETROSPECTIVE US CLAIMS DATA STUDY DISEASE: NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS, ONCOLOGY	Collin S, Shaikh N, Tse J, Near A, Shah C, Traina T, Bhavne M
EPIDEMIOLOGY & PUBLIC HEALTH	EPH67	ASSOCIATION BETWEEN POLYPHARMACY AND COGNITIVE LIMITATIONS AMONG ADULTS WITH DEPRESSION IN THE UNITED STATES DISEASE: NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS, MENTAL HEALTH (INCLUDING ADDICTION)	Shaikh M, Ikram M, Shaikh N
HEALTH POLICY & REGULATORY	HPR45	THE COST OF 340B TO STATES DISEASE: NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS	Sun C, Zeng S, Campbell J, Motyka J, Westrich K, Martin R
PATIENT-CENTERED RESEARCH	PCR33	DEVELOPMENT OF NEW PATIENT REPORTED OUTCOME (PRO) CONCEPTUAL MODELS FOR TREATMENT ADHERENCE AND SATISFACTION IN PEOPLE WITH HIV DISEASE: NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS, INFECTIOUS DISEASE (NON-VACCINE) TREATMENT AREAS	Chen M, Navadeh S, Vandenberg G, Park S, Bogart M, Altman D, Rosenberger-Yunger Z, Baldasaro J, Chatha C, Schmidt K
	PCR56	TRANSLATION AND CULTURAL ADAPTATION OF THE PAIN IMPACT QUESTIONNAIRE (PIQ-6) AMONG CHRONIC PAIN PATIENTS IN JAPAN DISEASE: NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS, SYSTEMIC DISORDERS/CONDITIONS (ANESTHESIA, AUTO-IMMUNE DISORDERS (N.E.C.), HEMATOLOGICAL DISORDERS (NON-ONCOLOGIC), PAIN)	Morishita A, Yakushiji A, Watanabe L, Higa S, Watanabe K, Sasanami M, Demiya S, Idehara K
	PCR94	USE OF DIARIES TO CAPTURE PATIENT-REPORTED OUTCOMES IN FDA NEW DRUG APPROVALS (2019-2023) DISEASE: NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS	Sauchelli S, Chicklis E, Carty M, Gnanasakthy A
REAL WORLD DATA & INFORMATION SYSTEMS	RWD53	BURDEN OF ILLNESS AND HEALTHCARE RESOURCE UTILIZATION (HCRU) FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ONTARIO, CANADA DISEASE: NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS, RESPIRATORY-RELATED DISORDERS (ALLERGY, ASTHMA, SMOKING, OTHER RESPIRATORY)	Garces K, Orava E, Thabane M, Ng G
	RWD63	REAL-WORLD PATIENT PERSISTENCE AND ADHERENCE: A COMPARISON OF LONG ACTING INJECTABLES AND ORAL ANTIPSYCHOTICS USED FOR THE TREATMENT OF SCHIZOPHRENIA IN A CANADIAN ADULT POPULATION DISEASE: NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS	Feener S, Ng R, Barbeau M, Houle G, Fraeic A

Further details of poster presentations at ISPOR 2025 are available at www.ispor.org

POSTER SESSION 3 • THURSDAY, MAY 15 • 10:30AM–1:30PM

 PRESENTING AUTHORS WILL ATTEND THEIR POSTERS FROM 12:30PM–1:30PM

TOPIC	CODE	TITLE	AUTHORS
ECONOMIC EVALUATION	EE222	BUDGET IMPACT MODEL TO EVALUATE THE INCLUSION OF A PRE-FILLED SYRINGE COMPARED TO VIAL APPLICATION OF DENOSUMAB IN PATIENTS WITH FOUR CANCER TYPES IN MEXICO DISEASE: ONCOLOGY	Cruz B, Lopez V, Góngora DS
	EE223	HEALTHCARE RESOURCE UTILIZATION AND ECONOMIC BURDEN OF CONGENITAL HYPERINSULINISM (CHI) IN THE UNITED STATES (US) DISEASE: NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS, RARE & ORPHAN DISEASES	Doshi R, Baugh B, Morgan B, DeKoven M, Tse J, Gondolf T, Kloster B
	EE235	ASSESSING RISDIPLAM COST-EFFECTIVENESS FOR SPINAL MUSCULAR ATROPHY TYPES I, II, AND III IN CHILE DISEASE: MUSCULOSKELETAL DISORDERS (ARTHRITIS, BONE DISORDERS, OSTEOPOROSIS, OTHER MUSCULOSKELETAL), NEUROLOGICAL DISORDERS, RARE & ORPHAN DISEASES	Góngora DS, Tamayo C
	EE274	EPIDEMIOLOGICAL ANALYSIS AND PATIENT PROFILE OF LUNG CANCER IN THE BRAZILIAN PUBLIC HEALTH SYSTEM: A REAL-WORLD DATA STUDY DISEASE: ONCOLOGY	Almeida A, Berra T, Santos A, Vitorasso R, Martins C, Jabase L
HEALTH POLICY & REGULATORY	HPR83	CHINA'S NATIONAL REIMBURSEMENT DRUG LIST (NRDL) NEGOTIATION: VALUE CONSIDERATIONS AND KEY FACTORS INFLUENCING PAYMENT STANDARDS DISEASE: NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS	Wu Y, Mo X, Zhao J, Ming J, Liu J, Wei T, Chen W
PATIENT-CENTERED RESEARCH	PCR131	LINGUISTIC INCONSISTENCIES RELATED TO NAVIGATION BUTTONS IN ELECTRONIC PATIENT-REPORTED OUTCOME MEASURES DISEASE: NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS	Hughes L, Marszewska J, Frau-Méndez M, Josielewski E

POSTER SESSION 4 • THURSDAY, MAY 15 • 4:00PM–7:00PM

 PRESENTING AUTHORS WILL ATTEND THEIR POSTERS FROM 6:00PM–7:00PM

TOPIC	CODE	TITLE	AUTHORS
ECONOMIC EVALUATION	EE342	HEALTHCARE UTILIZATION AND COST OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN ONTARIO, CANADA: AN OBSERVATIONAL STUDY DISEASE: DIABETES/ENDOCRINE/METABOLIC DISORDERS (INCLUDING OBESITY)	Patel K, Moreno Baca D, Konstantelos N, Ng G, Lathia U
	EE363	TREATMENT PATTERNS AND TOTAL HEALTHCARE COSTS ASSOCIATED WITH PATIENTS WITH MULTIPLE MYELOMA IN THE UNITED STATES: A LARGE ADMINISTRATIVE CLAIMS DATABASE ANALYSIS DISEASE: NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS, ONCOLOGY	Suvannasankha A, Zhao X, Ting J, Hasegawa K, Chan R, Itani T, Giordana M, Granados E, Near A
	EE419	COST-EFFECTIVENESS ANALYSIS OF BIVALENT RESPIRATORY SYNCYTIAL VIRUS PREFUSION F VACCINE FOR ADULTS 60 YEARS OF AGE AND OLDER IN JAPAN DISEASE: RESPIRATORY-RELATED DISORDERS (ALLERGY, ASTHMA, SMOKING, OTHER RESPIRATORY), VACCINES	Hirano Y, Komiya K, Kamei K, Yoshida A, Morii J, Kobayashi R, Sato R
EPIDEMIOLOGY & PUBLIC HEALTH	EPH121	NAVIGATING REAL-WORLD DATA (RWD) COMPLEXITIES: OPERATIONAL ASSESSMENT STRATEGY TO IDENTIFY FIT-FOR-PURPOSE DATA SOURCES FOR REAL-WORLD EVIDENCE (RWE) STUDIES WITH REGULATORY PURPOSE (OASIS) DISEASE: NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS	Lundin A, Drummond S, Vian Ma, Hetemäki S, Hou K, Engel P
HEALTH SERVICE DELIVERY & PROCESS OF CARE	HSD80	ASSESSING REAL-WORLD DOSING PATTERNS FOR VESICULAR MONOAMINE TRANSPORTER-2 INHIBITORS (VMAT2I), VALBENAZINE AND DEUTETRABENAZINE, AMONG PATIENTS WITH TARDIVE DYSKINESIA (TD) IN A NATIONWIDE US CLAIMS DATABASE DISEASE: MENTAL HEALTH (INCLUDING ADDICTION), SDC: NEUROLOGICAL DISORDERS	Perez-Rodriguez M, Nedzesky J, Serbin M, Divino V, Pandya S, Doshi R, Zhou X, Nedzesky J, Kim H, Vanderhoef D, Bron M

Further details of poster presentations at ISPOR 2025 are available at www.ispor.org

POSTER SESSION 4 • THURSDAY, MAY 15 • 4:00PM–7:00PM *continued*

 PRESENTING AUTHORS WILL ATTEND THEIR POSTERS FROM 6:00PM–7:00PM

TOPIC	CODE	TITLE	AUTHORS
PATIENT-CENTERED RESEARCH	PCR173	PSYCHOMETRIC EVALUATION OF THE MASTOCYTOSIS SYMPTOM SEVERITY DAILY DIARY (MS2D2) INSTRUMENT IN PATIENTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS (NONADVSM) DISEASE: RARE & ORPHAN DISEASES, SYSTEMIC DISORDERS/CONDITIONS (ANESTHESIA, AUTO-IMMUNE DISORDERS (N.E.C.), HEMATOLOGICAL DISORDERS (NON-ONCOLOGIC), PAIN)	Marcus J, Akin C, Turner R, Zhang J, Easton R, Lim-Watson M, Carden M, Siebenhaar F
REAL WORLD DATA & INFORMATION SYSTEMS	RWD133	BUILDING ON 'CONTEMPORARY PRACTICE AND CONSIDERATIONS FOR REAL-WORLD DATA (RWD) SOURCE IDENTIFICATION AND FEASIBILITY ASSESSMENT': MAPPING FEASIBILITY CRITERIA ACROSS 46 REAL-WORLD EVIDENCE (RWE) GUIDELINES DISEASE: NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS	Drummond S, Heidt J, Layton D, Patel D
STUDY APPROACHES	SA58	LARGE LANGUAGE MODELS FOR AUTOMATIC PICO CRITERIA EVALUATION DISEASE: CARDIOVASCULAR DISORDERS (INCLUDING MI, STROKE, CIRCULATORY), DIABETES/ENDOCRINE/METABOLIC DISORDERS (INCLUDING OBESITY)	Filomeno F, Mendes Pereira L, Watanabe L, McGuinness N

POSTER SESSION 5 • FRIDAY, MAY 6 • 9:00AM–11:30AM

 PRESENTING AUTHORS WILL ATTEND THEIR POSTERS FROM 9:00AM–10:00AM

TOPIC	CODE	TITLE	AUTHORS
CLINICAL OUTCOMES	CO197	THE EVOLUTION OF LANGUAGE IN CLINICAL OUTCOME ASSESSMENTS- AN ANALYSIS OF SOURCE WORDING UPDATES, TRANSLATION UPDATES, AND THE NEED TO PERIODICALLY ASSESS THE REVELANCE OF LINGUISTICALLY VALIDATED TRANSLATIONS DISEASE: NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS	McKown S, Simpson-Finch H, Rees E, Miller K, Japheth Benablo P
ECONOMIC EVALUATION	EE427	REAL-WORLD LONG-TERM CLINICAL AND ECONOMIC OUTCOMES OF PRETERM INFANTS WITH NEONATAL RESPIRATORY DISTRESS SYNDROME IN THE UNITED STATES DISEASE: PEDIATRICS, RESPIRATORY-RELATED DISORDERS (ALLERGY, ASTHMA, SMOKING, OTHER RESPIRATORY)	Colucciello A, Meshchenkova N, Munnangi S, Tse J, DeKoven M, Fabbri L, Abman S
EPIDEMIOLOGY & PUBLIC HEALTH	EPH188	ECONOMIC MODELLING OF MYOPIA MANAGEMENT: A SYSTEMATIC LITERATURE REVIEW DISEASE: PEDIATRICS, SENSORY SYSTEM DISORDERS (EAR, EYE, DENTAL, SKIN)	de Milliano T, Wielink K, Li J, Ernst F, Lymperopoulou C, Veeranki P, Mulkalapalli N, Pagidigumula R
REAL WORLD DATA & INFORMATION SYSTEMS	RWD139	BURDEN OF HIDRADENITIS SUPPURATIVA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM DISEASE: SYSTEMIC DISORDERS/CONDITIONS (ANESTHESIA, AUTO-IMMUNE DISORDERS (N.E.C.), HEMATOLOGICAL DISORDERS (NON-ONCOLOGIC), PAIN)	Bigoni A, Tozato C, Almeida A, Leonel L, Goularte-Silva V, Vallilo C
	RWD165	PIONEERING THE INTEGRATION OF HEALTH-EQUITY VARIABLES INTO AN ADMINISTRATIVE CLAIMS DATABASE: A STEP FORWARD IN THE JOURNEY TO SUPPORTING UNDERSERVED POPULATIONS DISEASE: NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS	Wang R, To T, Jhuti G, Borel S, Mak G, Safari M
STUDY APPROACHES	SA78	PERFORMANCE OF UNANCHORED POPULATION-ADJUSTED INDIRECT COMPARISON METHODS IN RARE DISEASE SETTINGS: A SIMULATION STUDY DISEASE: NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS, RARE & ORPHAN DISEASES	Boyne D, Sohn A, Lindsley K, Nikolaidis G, Tassoulas A, Uyei J, Cappelleri J, Kim R, Chu H

Further details of poster presentations at ISPOR 2025 are available at www.ispor.org

Patient-centricity in the Biopharmaceutical Industry: Are We Nearly There Yet?

A collection of perspectives from researchers, approvers and patients

Collated and edited by Dr. Matthew Reaney

A new book compiled by the Patient Centered Solutions team at IQVIA gathers insights on patient-centric intervention development from a diverse group of more than 30 experts. In formats ranging from reviews of their research and personal narratives to poetry and short fiction, the contributors share their thoughts on where patient-centricity stands today, what improvements are still to be made, and how the voice of the patient will influence the future of healthcare.

Contributors include:


- Pharma company executives
- Small biotechnology manufacturers
- Patient representatives
- Patient advocacy group (PAG) leaders
- Patient experience data (PED) researchers
- Regulatory representatives
- Payer and health technology agency (HTA) advisors



Stop by our booth to reserve a copy
or download for free at
bit.ly/PatientCentricityBook

*“Always, always, always involve patients
in the development of anything.”*

Patient with multiple sclerosis speaking
to the Accelerated Cure Project



Contact us at PCSBD@IQVIA.com to learn how IQVIA's PCS team
can help ensure that your research is truly patient-centric

CONTACT US
iqvia.com

